Agastiya Biotech and Vopec Pharmaceuticals are delighted to announce that the US FDA has awarded Orphan Drug Designations for Glioblastoma, Pancreatic and Acute Myeloid Leukemia indications for AB001. These rare cancers are generally considered a death sentence. AB001 may prove to be the answer,.
We create toxicity-free / negligibly toxic small molecules, an unmet need of the pharmaceutical industry. Toxicity is the biggest challenge in drug discovery. It not only delays the drug approval process but results in less efficacy and drives up drug costs.
Our portfolio of 120 small molecules has no toxicity/negligible toxicity covering a wide variety of cancer indications, neurodegenerative diseases such as Alzheimer’s, Parkinson’s, dementia, depression, diabetes, life extension telomere technology, and others.
Our strategic approach is to use the enormous generic manufacturing resources in India and combine it with preclinical and clinical trial segments. With the help of the Indian Government’s “Make in India” platform.
Pharma pricing has been the biggest issue debated by the US lawmakers, White House and general public. Agastiya Biotech’s strategy to “Make in India” will be beneficial for the US to cut cost and at the same time will be a great financial opportunity for India.
Our Programs
Anti-viral Therapeutics for Sars-Cov-2
Agastiya Biotech has studied its previously tested anti-cancer small molecule AB001 blocks Sars-CoV-2 virus therapeutics in silico studies.
Cancer Drug
Development
We are developing novel molecular formulations for breakthrough therapies in cancer stem cells, tumor supressor genes and oncogene mutations.
Psoriais
Psoriais is a chronic, immune-mediated, inflammatory relapsing systemic skin disorder that predominantly involves the skin, nails, and joints with intermittent.
Discovery Renaissance
We’re identifying the undeniable synergy between
neurons, nature and genetics overlaid
with time tested algorithms.